DeepMed Research

MannKind Corp

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 414

Market Cap: $1.4B

Website

Clinical Trials

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TI-Inhalation Powder A
Drug: TI-Inhalation Powder B

First Posted Date: 2013-11-13

Last Posted Date: 2014-10-02

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 38

Registration Number: NCT01982604

Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Technosphere® Insulin 10U + 20U
Drug: Technosphere® Insulin 30U

First Posted Date: 2013-07-18

Last Posted Date: 2014-12-12

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 40

Registration Number: NCT01902121

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Conditions: Type 1 Diabetes
Type 2 Diabetes

First Posted Date: 2013-02-26

Last Posted Date: 2016-01-20

Lead Sponsor: Mannkind Corporation

Registration Number: NCT01798914

Locations: 🇺🇸
Endocrinology Associates, Montgomery, Alabama, United States
🇺🇸
Diabetes and Endocrine Consultants P.C., Montgomery, Alabama, United States
🇺🇸
Dr. Rife and Associates Family Medicine, Orland Park, Illinois, United States

and more 11 locations

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Technosphere Insulin Inhalation Powder
Drug: Rapid Acting Analog

First Posted Date: 2012-03-06

Last Posted Date: 2013-01-25

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 17

Registration Number: NCT01544881

Locations: 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Regular Human Insulin
Drug: Technosphere Insulin Inhalation Powder using the Gen2C inhaler

First Posted Date: 2011-12-13

Last Posted Date: 2012-09-07

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 35

Registration Number: NCT01490762

Locations: 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Technosphere® Insulin
Drug: Technosphere Powder

First Posted Date: 2011-10-13

Last Posted Date: 2014-10-17

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 353

Registration Number: NCT01451398

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Insulin Aspart in combination with a basal insulin
Drug: Technosphere® Insulin with MedTone C Inhaler
Drug: Technosphere ®Insulin with Gen2 Inhaler

First Posted Date: 2011-10-04

Last Posted Date: 2014-10-22

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 518

Registration Number: NCT01445951

Pharmacokinetic Study in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Technosphere® Insulin Inhalation Powder

First Posted Date: 2011-06-03

Last Posted Date: 2012-06-14

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 50

Registration Number: NCT01365117

Locations: 🇺🇸
Celerion, Neptune, New Jersey, United States

Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166

Terminated

Conditions: Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus

Interventions: Drug: Comparator administered in parent trial
Drug: Technosphere Insulin Inhalation Powder

First Posted Date: 2010-09-15

Last Posted Date: 2012-12-06

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 3

Registration Number: NCT01201928

Locations: 🇺🇸
Billings Clinic Research Center, Billings, Montana, United States
🇺🇸
SAM Clinical Research Center, San Antonio, Texas, United States
🇺🇸
Valley Research, Fresno, California, United States

and more 11 locations

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

Phase 3

Terminated

Conditions: Type 2 Diabetes

Interventions: Drug: Technosphere® Insulin Inhalation Powder
Drug: Insulin Aspart
Drug: Insulin Glargine

First Posted Date: 2010-09-08

Last Posted Date: 2014-10-30

Lead Sponsor: Mannkind Corporation

Target Recruit Count: 39

Registration Number: NCT01196104

Locations: 🇺🇸
Billings Clinic Research Center, Billings, Montana, United States
🇺🇸
Diabetes Research Center -Fletcher Allen Health Care, South Burlington, Vermont, United States
🇺🇸
Coastal Clinical Research Inc, Mobile, Alabama, United States

and more 26 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy